Description: Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and The Boeing Company (BA), as well as a micro-cap stock Tandy Leather Factory, Inc. (TLF).

Description: According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Description: Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and

Description: AbbVie (ABBV) is entering the PD-1/VEGF cancer treatment class, a competitive emerging area for soli

Description: Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S

Description: AbbVie agreed to lower Medicaid prices and invest $100 billion in the US in exchange for tariff and pricing relief.

Description: AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.

Description: Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Bipolar Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a

Description: AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.

Description: $100 billion U.S. investment anchors agreement

Description: We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]

Description: AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of its US footprint.

Description: Shifting regulatory policies and evolving US drug pricing dynamics have created a favourable environment for deals.

Description: AbbVie has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs. The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development. AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.

Description: North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future price mandates, the company announced Monday evening. Under the voluntary agreement, AbbVie will offer “low prices” in Medicaid, a state and federally funded health insurance program for people with low incomes and ...

Description: As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on details as well as its potential financial impact.

Description: As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.

Description: AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation.

Description: Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67

Description: AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals expected in the coming days.

Description: ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.

Description: Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.

Description: AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.

Description: AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.

Description: West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing condit

Description: AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie's drug delivery device manufacturing capabilities and capacity.

Description: The decision about buying these dividend stocks is an easy one.

Description: Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in South Korea. Samil, established in 1947, is one of the most prominent Korean manufactu

Description: CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc

Description: AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer Perform from Outperform on January 8 by Wolfe Research without a price target. The firm stated that the shares already reflect outperformance expectations in Skyrizi and Rinvoq, which is why it is moving to the […]

Description: Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people familiar with the matter. A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail. Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.

Description: AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to roughly US$244.56 per share, even as analysts reassess the story around its key drug franchises. The discount rate and long term revenue growth assumptions have been tweaked only slightly, reflecting how bullish and bearish views are being fine tuned rather than completely rewritten as new research lands. Read on to see how you can keep on top of these small but...

Description: Add some stability to your holdings with these healthcare giants.

Description: Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.

Description: NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

Description: ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.

Description: Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.

Description: If you are wondering whether AbbVie at around US$224 per share still offers value, or if most of the opportunity is already priced in, this article is for you. The stock is roughly flat over the last month with a 0.5% return, but that sits alongside a 30.0% return over 1 year and 141.2% over 5 years, which can change how investors think about both risk and potential reward. Recent headlines have focused on AbbVie’s position as a major US pharmaceuticals and biotech player and how its...

Description: Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.

Description: Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock closed higher by 5% Thursday and added another 15% after-hours following a Financial Times report that Merck (NYSE:MRK) is in talks to acquire the biotech company.

Description: Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 0.7% and t

Description: The Dow Jones Industrial Average was up, the S&P 500 was roughly flat, and the Nasdaq Composite was

Description: Drugmaker says acquired IPR&D and milestone expenses will weigh on Q4 2025 and full-year earnings guidance.

Description: Last year marked the third straight year of double-digit gains for the S&P 500. A fourth consecutive year is far from guaranteed.

Description: AbbVie on Thursday denied that it is in talks to buy cancer-drug biotech Revolution Medicines, sending both stocks lower ahead of the opening bell. “AbbVie is not in talks to acquire Revolution Medicines,” an AbbVie spokesperson told Barron’s. The Wall Street Journal reported on Wednesday that the two companies were close to a deal, citing people familiar with the matter. AbbVie stock fell 1.6% to $229.61 on Thursday, having jumped 4.2% the previous session following The Journal’s report.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr

Description: Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.

Description: Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.

Description: JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.

Description: Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,

Description: AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...

Description: We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]

Description: AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter, in what would be one of the year’s first megadeals. A deal could come together soon, granted the talks don’t hit any last-minute snags, the people said. After The Wall Street Journal reported on the deal talks, AbbVie said it “is not in discussions” with Revolution.

Description: By Puyaan Singh Jan 7 (Reuters) - AbbVie on Wednesday denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker was in advanced discussions to acquire the

Description: Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th

Description: Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock surged 29% before trading was halted twice due to volatility following a Wall Street Journal report that AbbVie (NYSE:ABBV) is in advanced talks to acquire the clinical-stage precision oncology company.

Description: AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...

Description: The iShares Core High Dividend ETF (NYSEARCA:HDV) offers retirees a 3.3% yield with 0.08% fees, tracking high-quality U.S. dividend payers. The fund generates income from dividends of blue-chip stocks concentrated in Consumer Staples (28%), Energy (24%), and Healthcare (17%). With $11.8 billion in assets and a 14-year track record, HDV appeals to income-focused investors. However, ... What Retirees Need To Know About HDV’s Dividend Before Buying

Description: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Description: AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

Description: AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.2 It is the first and only oral eight-week pan-genotypic treatment option approved in Canada.

Description: The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close.

Description: Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

Description: AbbVie (ABBV) has been drawing fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months as investors reassess its large biopharma portfolio. See our latest analysis for AbbVie. At a share price of US$229.31, AbbVie’s short term share price returns have been fairly muted, while its 1 year total shareholder return of 31.78% and 5 year total shareholder return of 155.61% point to sustained investor interest. Earlier...

Description: The WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS) offers retirees monthly income and capital appreciation. With $1.3 billion in assets and a 3.46% yield, this ETF holds diversified high-dividend U.S. equities. The fund’s defensive tilt (41% in consumer staples, healthcare, and utilities) provides stability, while its 0.38% expense ratio keeps costs low. DHS delivers monthly distributions, ... The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS

Description: As the AI trade becomes "fractured," 2026 could see other stocks finally outshine the "Magnificent Seven."

Description: AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.

Description: Rosacea is a chronic skin condition that presents as facial redness, visible blood vessels, and acne-like bumps, affecting the face, neck, chest, and eyes. The global rosacea market is experiencing growth propelled by increasing cases in adults aged 30-60, expanded awareness, and newly approved treatments like Emrosi and Rhofade. Barriers such as high medication costs and underdiagnosis in darker skin tones remain. However, innovative therapies, the rise of teledermatology, and personalized skin

Description: Buffett is no longer at the helm of Berkshire Hathaway. But his investing wisdom remains relevant.

Description: It won't happen overnight, but patience will be rewarded.

Description: The company said it expects total revenue of between $450 million and $475 million this year, up from the $290 million to $310 million it had told investors to expect for 2025.

Description: ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.

Description: Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Description: Ironwood Pharmaceuticals (IRWD) shares jumped early Friday after the biotechnology company said it e

Description: ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.

Description: AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Description: AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating. The firm said it sees “a relatively clean setup” for growth near the top end of the […]

Description: You don't need to settle for an average dividend yield.

Description: Miramar Capital's Max Wasserman forecasts a "broadening" of the market in 2026.

Description: Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.

Description: If you're hunting for dividend stocks, don't overlook these businesses.

Description: It is wrapping up another great year, and there is no sign of a slowdown.

Description: If you're investing for the long run, there are a myriad of companies begging to be bought.

Description: Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.

Description: ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.

Description: These two are the calm outperformers that might have been overlooked.

Description: AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.

Description: Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.

Description: Growth and income investors can buy these five top dividend stocks now, tomorrow, next week, or next year and hold for the long term.

Description: As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Dow Jones Industrial Average nearing record highs, investors are increasingly on the lookout for opportunities that may be flying under the radar. In such a climate, identifying stocks that are estimated to be trading below their fair value can offer potential pathways to capitalize on market movements, especially when tech shares lead the charge and precious metals hit fresh records.

Description: Catalyst Funds chief investment officer and senior portfolio manager David Miller and Marketgauge.com chief strategist Michele Schneider join Morning Brief host Julie Hyman to share some of their top stock picks in the healthcare (XLV) sector. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.

Description: Earlier in December 2025, OSE Immunotherapeutics amended its partnership with AbbVie over the inflammatory disease candidate ABBV-230, with OSE taking back control of preclinical and Phase 1 work, at its own funding risk, while AbbVie kept exclusive rights to later-stage development and commercialization on unchanged economic terms. The revised ABBV-230 arrangement underlines AbbVie’s willingness to lean on partners’ early-stage immunology expertise while reserving control of potential...

Description: XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Description: Investors can expect steady dividend returns with these stocks.

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Exploring the Fund's Recent Portfolio Adjustments

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige

Description: Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.

Description: AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

Description: FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science a

Description: If you are depending on Social Security for your retirement income, you might want to add reinforcements. While Social Security is tweaked annually in an attempt to keep up with the pace of inflation, its buying power has been dwindling in recent decades while the core inflation rate of 3% continues to hover above the ... The 3 Income ETFs I’d Use to Offset Social Security

Description: J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Description: We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even as the company’s core business fundamentals remain solid. […]

Description: Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.

Description: As December 2025 unfolds, the U.S. stock market faces a challenging period with major indices like the S&P 500 and Dow Jones Industrial Average experiencing consecutive declines amid AI bubble concerns and rising unemployment rates. In such an environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.

Description: Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Description: Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term prospects. AbbVie has climbed 24.6% year to date and 32.0% over the last year, even after a softer last month with a 3.7% pullback from recent highs to around $223.67. That mix of strong multi year gains and short term wobble is exactly when valuation matters most. Recently, investors have been...

Description: BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper

Description: Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded

Description: The latest trading day saw AbbVie (ABBV) settling at $227.45, representing a +1.85% change from its previous close.

Description: An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

Description: AbbVie (ABBV) has a relatively clean growth profile with limited loss of exclusivity and growth like

Description: Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through recessions, market crashes, and business disruptions. We ranked them by dividend growth consistency, payout sustainability, and business resilience heading into 2026. ... The Best Dividend Stocks for Retirement Portfolios in 2026

Description: AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines.

Description: AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly results, higher earnings guidance, and another dividend increase. See our latest analysis for AbbVie. Even with a softer 1 month share price return of 4.25 percent, AbbVie’s 24.45 percent year to date share price gain and 33.32 percent 1 year total shareholder return show momentum is still firmly building, helped by upbeat trial data, pipeline updates, and that fresh...

Description: These habitual market beaters can pull it off again.

Description: Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine

Description: They could grow into their valuation over the next few years.

Description: Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands of publicly traded companies, only a select few have proven they can grow dividends through recessions, market crashes, and industry upheaval. We ranked these six proven dividend winners ... Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks

Description: AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

Description: See what solid dividends do for a portfolio after just five years.

Description: The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.

Description: A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.

Description: Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...

Description: The drugmaker has plenty to offer investors.

Description: The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The "Non-Opioid Therapeutics Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi

Description: ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

Description: AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]

Description: Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom. The sector’s relative earnings growth averaged just 6% annually over that stretch, trailing the S&P 500‘s 15%, but signs of stabilization emerged ... This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Description: AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.

Description: As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.

Description: The Global X SuperDividend ETF (NYSEARCA:SDIV) generates its 8% yield by investing in 100 of the highest dividend-yielding equities across global markets. The fund holds stocks from developed and emerging markets spanning telecommunications, energy, materials, financials, and real estate. Income comes directly from dividends paid by underlying companies, making SDIV’s distributions entirely dependent on whether ... At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High In

Description: Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More

Description: Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.

Description: As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.

Description: The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin

Description: Blockbuster drugs are a major driver of the growth of healthcare stocks.

Description: Great dividends are only part of the attraction with these stocks.

Description: AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...

Description: AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.

Description: In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...

Description: With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Description: OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati

Description: In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.

Description: This drugmaker has a strong portfolio of best-selling drugs and a growing pipeline.

Description: Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.

Description: Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Don't bet against it.

Description: ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.

Description: The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

Description: AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: If you are wondering whether AbbVie is still attractive after its huge run, or if you are late to the party, you are in the right place to unpack what the current share price really implies. Even after a strong long-term climb, with the stock up 27.9% over the last year and 153.2% over five years, recent returns have cooled a bit, with a 3.2% dip in the last week but still a 2.9% gain over the past month and 25.0% year to date. Investors have been reacting to ongoing developments around...

Description: By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth and leadership in rare and inflammatory diseases,” said Kenji Cunnion, M.D., MPH, ReAlta’s co-founder, Chief […]

Description: AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investiga

Description: These healthcare leaders can make you money while you sleep.

Description: Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generi

Description: AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set to report its Q4 2025 earnings on Jan. 30. Wall Street analysts expect the company to post EPS of $3.36, up from ...

Description: AbbVie Inc.'s ( NYSE:ABBV ) dividend will be increasing from last year's payment of the same period to $1.73 on 17th of...

Description: These stocks have been raising their dividend payments annually for well over a decade, and they pay more than twice the S&P 500 average.

Description: AbbVie (ABBV) shares are holding steady as investors assess the company’s ongoing performance following recent earnings. With key drugs still leading the portfolio, many are watching how AbbVie manages steady growth in a competitive sector. See our latest analysis for AbbVie. AbbVie’s share price has steadily climbed this year, with a year-to-date return of nearly 27%. The company’s recent updates have not slowed its momentum, as investor confidence continues to build. This is reflected in an...

Description: SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f

Description: Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Description: Most of the market was feasting on another helping of Thanksgiving week gains on Wednesday, but enterprise software and health care stocks were missing out on the celebration. Workday was the biggest laggard in the S&P 500 and among the fewer than 90 stocks in the index that were trading lower on Wednesday. Salesforce, another major player in enterprise software, reports quarterly results a week from today.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Description: National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tod

Description: Analysts have recently nudged AbbVie's consensus price target upward, rising slightly from $241.29 to $243.55 as updated sentiment filters through the market. This shift reflects increased optimism driven by strong performance in key growth areas and strategic business moves. Stay tuned to find out how investors can stay informed on evolving perspectives and future updates in AbbVie’s dynamic story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...

Description: AbbVie recently received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of adults with relapsed or refractory follicular lymphoma, following robust Phase 3 results showing significant improvement over standard of care. This landmark regulatory milestone addresses an unmet need in a challenging lymphoma type, potentially expanding AbbVie's reach in oncology and advancing treatment standards for patients with limited...

Description: AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time.

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: Investors should be able to count on steady dividends from these great stocks.

Description: In the last year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a substantial stake in the company which may have...

Description: JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Description: LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.

Description: ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face. Unexpected market moves are hard to predict, and if you could make such predictions, not only would you be rich, but people would be throwing money at you, literally, to invest it ... 2 Dividend Stocks to Hold Through Any Market Cycle

Description: The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco

Description: AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Description: As the U.S. stock market experiences a period of volatility, with major indices like the S&P 500 and Dow Jones Industrial Average facing consecutive declines, investors are keenly observing the impact of high valuations in sectors such as technology. Amidst these fluctuations, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to navigate current market conditions wisely.

Description: A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

Description: Wondering if AbbVie is a smart buy at today's price? You're not the only one. Let's dig into the numbers to find out how the market might be valuing the stock right now. AbbVie’s share price has jumped 7.0% in the past week and surged 30.4% year-to-date, putting its performance firmly in the spotlight and hinting at shifting investor sentiment. This momentum hasn’t come out of nowhere. Investors are reacting to positive developments from AbbVie’s drug pipeline and several high-profile FDA...

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal

Description: AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to st

Description: The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam

Description: ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.

Description: It's no reason to stay up at night.

Description: AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana

Description: AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...

Description: These stocks pay income that investors can count on over the long run.

Description: AbbVie (ABBV) is back in the spotlight after announcing strong quarterly results and a 6% dividend increase. The company also made waves by shifting strategy away from its Calico Life Sciences partnership and updating investors on several fronts. See our latest analysis for AbbVie. AbbVie shares have outpaced much of the market lately, supported by upbeat earnings, a hefty dividend increase, and high-profile strategic refocusing. With a 29% year-to-date share price return and a standout 46%...

Description: AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.1,2 Each person's dynamic story reveals how facing a life-changing diagnosis can bring clarity and purpose, sparking a renewed commitment to staying active and embracing what truly matters in their lives.

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

Description: New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab.Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape, as rheumatologists expand use of next-generation IL-17 and JAK

Description: Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing

Description: Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Wall Street closed mixed on Wednesday, pulled up by healthcare and financial stocks.

Description: Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

Description: AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.

Description: As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Description: These top dividend payers could enrich a long-term investor's portfolio.

Description: BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel

Description: As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this environment, identifying stocks that may be undervalued becomes crucial, as these investments could offer opportunities for growth when priced below their intrinsic value.

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.

Description: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the […]

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, November 13-16, 2025, in Chicago, Illinois. Oral and video poster presentations, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering scientific research and innovation.

Description: PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging disease areas with high unmet need. “This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive

Description: As the U.S. stock market rebounds amid optimism for a resolution to the prolonged government shutdown, investors are eyeing opportunities within this volatile landscape. In such times, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts, as these stocks may offer significant value relative to their current trading prices.

Description: As the U.S. stock market navigates a period of mixed performance, with major indices like the S&P 500 and Nasdaq showing slight declines following an early-week rally, investors are closely monitoring developments such as the potential end to the government shutdown. In this environment, identifying stocks that may be undervalued becomes crucial for investors seeking opportunities amid fluctuating tech stock performances and broader market shifts.

Description: Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.

Description: As the United States stock market experiences a surge in optimism due to potential resolutions to the government shutdown, major indices like the Nasdaq, S&P 500, and Dow Jones have posted significant gains. In this environment of renewed investor confidence, identifying undervalued stocks can be particularly advantageous as they may offer opportunities for growth amidst market fluctuations.

Description: AbbVie’s consensus analyst price target has inched up from $237.48 to $241.29, reflecting renewed optimism surrounding the stock’s outlook. This slight boost is attributed to strong sales for core immunology treatments and an extended exclusivity window for Rinvoq, in addition to ongoing strategic developments. As analysts evaluate these catalysts alongside lingering concerns, readers should stay tuned for insights on monitoring evolving opinions and updates in the months ahead. Stay updated...

Description: AbbVie recently reported third-quarter 2025 results, highlighted by a US$1.32 billion year-on-year increase in sales and a US$0.09 quarterly rise in its cash dividend to US$1.73 per share, but also announced a US$847 million intangible asset impairment and a significant drop in net income compared to the previous year. This period illustrates both AbbVie's ongoing emphasis on shareholder returns and the financial pressures from margin compression and asset write-downs. We'll examine how...

Description: With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?

Description: CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).

Description: Healthcare stocks in the S&P 500 offer an average dividend yield of 1.8%.

Description: These stocks are priced low, have encouraging growth prospects, and also pay dividends.

Description: AbbVie Inc. (NYSE:ABBV) is included among the 15 Best DRIP Stocks to Own Right Now. On November 5, Piper San‍dler​ analyst David Amsellem raised the price target on AbbVie Inc. (NYSE:ABBV) from⁠ $284 to $289 while maintaining an Over‌weight rating on the stock foll‌owing its quarte‍rly re​sults, as reported by The Fly. The analyst att‍ributed […]

Description: As the U.S. stock market navigates a challenging landscape with tech stocks under pressure and major indices experiencing significant losses, investors are keenly observing economic indicators like labor market data and Federal Reserve interest rate decisions. In this environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for growth amidst broader market volatility.

Description: AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and

Description: HORSHOLM, DENMARK / ACCESS Newswire / November 6, 2025 /Revenue and earnings for Gubra (CPH:GUBRA) reached record-high levels in the first nine months of 2025. Group revenue and adjusted EBIT amounted to DKK 2.6 billion and DKK 2.3 billion, respectively, ...

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

Description: Linzess becomes the first FDA-approved treatment for IBS-C in paediatric patients.

Description: REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025.

Description: Miramar Capital co-founder and senior portfolio manager, Max Wasserman, joins Morning Brief host Julie Hyman to discuss portfolio diversification and which stocks and sectors are poised to benefit as interest rates continue to come down. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: AbbVie Inc. (NYSE:ABBV) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the possible change in spending habits of the rich while discussing the stock, as he said: “AbbVie stock is still falling after management talked about slowing medical aesthetic sales. Botox for the face may have finally hit a wall, even […]

Description: AbbVie just increased its dividend by 5.5%, raising the quarterly payout to $1.73 per share starting February 2026, reflecting strong confidence in its long-term growth driven by new drugs like Skyrizi and Rinvoq.

Description: The choroidal neovascularization therapeutics market is expected to further increase due to major drivers, including the rising prevalence of the population, technological advancements, and upcoming therapies such as AbbVie and REGENXBIO’s ABBV-RGX-314, Adverum Biotechnologies’ Ixoberogene soroparvovec, Neuracle Genetics’ NG101, and others, during the forecast period (2025–2034).New York, USA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Choroidal Neovascularization Market to Witness Accelerated Growth Thr

Description: Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Description: WALTHAM, Mass., November 05, 2025--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies.

Description: Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628, an anti-PAPP-A monoclonal antibody, was developed by Calico in collaboration with AbbVie Inc. The the

Description: As the U.S. stock market experiences a pullback with major indices like the Dow Jones, Nasdaq, and S&P 500 showing declines, investors are increasingly cautious amid mixed earnings reports and fluctuating tech shares. In such an environment, identifying stocks that are trading below their fair value can offer potential opportunities for those looking to invest in assets that may be undervalued by the market.

Description: The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific. Hyperlipidemia Drugs Market Hyperlipidemia Drugs Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Hyperlipidemia Drugs Market Report 2025" has been added to ResearchAndMarkets.com's

Description: Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI bubble continue to mount. Tuesday’s sell-off follows a wild start to the week, during which the Dow Jones Industrial Average traded lower due ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More

Description: As the U.S. stock market navigates a mixed landscape, with the Nasdaq gaining momentum from tech deals and the Dow facing headwinds, investors are keenly focused on earnings reports and employment data amid a prolonged government shutdown. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities; these stocks are estimated to be trading significantly below their intrinsic value, offering possible long-term benefits amidst...

Description: Healthcare has been an extraordinarily resilient industry to put cash to work in through the years.

Description: BioSpace, the leader in biopharma news and careers, has published its 2026 Best Places to Work list.

Description: Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.

Description: Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]

Description: We recently published 10 Stocks Everyone’s Discussing Amid Latest Earnings Season. AbbVie Inc. (NYSE:ABBV) is one of the stocks everyone’s discussing. Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc (NYSE:ABBV) during a recent program on CNBC. ABBV shares are up 21% so far this […]

Description: This member of dividend royalty checks off lots of boxes for investors.

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: Some might call them boring businesses, but they have tremendous dividend growth track records.

Description: The market didn't exactly greet the company's latest earnings release with open arms.

Description: AbbVie (ABBV) reported revenue growth is expected at 6.8% per year, trailing the broader US market forecast of 10.3% per year. Earnings are projected to grow at 16% per year, just ahead of the US market average. Results this year were heavily impacted by a one-off loss of $14.5 billion in the last twelve months through September 30, 2025, with net profit margins dropping to 6.4% from 9.6% a year earlier. With a high price-to-earnings ratio of 103.5x and a five-year annual earnings decline of...

Description: AbbVie leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira, an analyst said Friday as AbbVie stock fell.

Description: AbbVie Inc (ABBV) surpasses earnings expectations with robust growth in immunology and neuroscience, despite facing significant Humira sales decline.

Description: Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including AbbVie (ABBV) shares sliding as the company raises its annual forecast on the success of its anti-inflammatory drugs, while Sharpie-parent company Newell Brands (NWL) stock plunges after cutting its full-year outlook on a challenging consumer environment tied to tariff price hikes. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.

Description: Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a reduced earnings forecast for the full year. Although AbbVie's quarterly revenue of $15.78 billion and adjusted earnings per share (EPS) of $1.86 both surpassed Wall Street's estimates, investors focused on underlying weaknesses. The company's operating margin fell sharply to 12.1% from 26.5% a year a

Description: Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.

Description: The Dow was struggling to stay above breakeven despite Amazon stock’s best efforts on Friday. The blue-chip index was moving in and out of negative territory. The S&P 500 was up 0.3%. The Nasdaq Composite was up 0.

Description: All three major US stock indexes were up in late-morning trading Friday as investors digested strong

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Reddit's (RDDT) stock surging after releasing strong third quarter revenue and advertising sales forecasts, AbbVie (ABBV) shares slumping on mixed drug sales in its third quarter, and Western Digital (WDC) topping its earnings expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: AbbVie (ABBV) raised its full-year outlook even as weakness in its Humira rheumatoid arthritis medic

Description: Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: AbbVie (ABBV) delivered earnings and revenue surprises of +5.08% and +1.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.

Description: Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.

Description: ABBV) on Friday reported third-quarter net income of $186 million. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 10 cents. Earnings, adjusted for amortization costs and asset impairment costs, were $1.86 per share.

Description: AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Friday, October 31, including earnings results from energy companies like Exxon Mobil (XOM), Chevron (CVX), and Dominion Energy (D), key commentary from a handful of Federal Reserve presidents, and the deadline for Disney (DIS) and YouTube (GOOG, GOOGL) to reach a new distribution deal. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the NSV indication.

Description: Today, AbbVie (NYSE: ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1

Description: Investors will tune into earnings from Amazon and Apple, plus the European Central Bank's interest-rate decision. Here’s what to watch for: Today Earnings: Amazon, Apple, Eli Lilly, Hershey, Mastercard Federal Reserve speaker: Vice Chair for Supervision Michelle Bowman at 9:55 a.

Description: Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to know.

Description: If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately. After an impressive 25.5% gain so far this year, shares have cooled off a bit over the past week, dropping 1.5%. Looking at the big picture, AbbVie’s long-term run has been nothing short of remarkable, with a 189.5% climb over five years. Moves like these naturally make investors wonder if the current price reflects genuine growth potential, or if the market is simply...

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November 19, 2025. This holiday honors the exceptional providers and valued patients who've contributed to the continued success of BOTOX® Cosmetic. As the biggest celebration of the year, BOTOX® Cosmetic Day champions those who count on the one and only BOTOX® Cosmetic by providing exclusive offers through Allē, the aesthetic loyalty program from Allergan Aes

Description: The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs. Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval. Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.

Description: AbbVie (ABBV) has seen its stock tick slightly lower this week, with shares down 0.2% today but still up 3% over the past month. Investors are weighing these recent moves along with long-term double-digit returns. See our latest analysis for AbbVie. Zooming out, AbbVie’s share price return over the past year highlights the stock’s strong upward momentum, and when you factor in dividends, its total shareholder return hits an impressive 24% for the year. That outperformance, combined with...

Description: AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4

Description: Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...

Description: Meta Platforms, Inc. (NASDAQ:META) is one of the stocks on Jim Cramer’s radar recently. A caller’s top five holdings were Meta, Microsoft, Walmart, Valero, and AbbVie, and they asked if their portfolio is diversified or not. In response, Cramer said: “Okay, so Valero, the margins are really good right now with oil versus gasoline. So […]

Description: Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Description: Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

Description: Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker.

Description: When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: Between growth and dividends, these companies have plenty to offer.

Description: AbbVie stock has seen its consensus analyst price target rise modestly from $232.78 to $237.48 per share. This change reflects evolving views in the wake of recent company updates. The shift is largely driven by extended product exclusivity and changing analyst sentiment tied to both opportunities and risks across AbbVie’s portfolio. Read on to learn how investors can keep pace with the latest shifts in AbbVie's narrative and stay informed about future developments. What Wall Street Has Been...

Description: Six of the world’s best AI chatbots received $10,000 to trade cryptocurrencies.The contest isn’t over yet, but most of them saw their portfolios take a beating. Why that shouldn’t be a surprise.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: The United States Breast Reconstruction Market is projected to grow from US$ 1.02 billion in 2024 to US$ 1.74 billion by 2033, with a CAGR of 6.1% from 2025 to 2033. Key factors driving this growth include rising breast cancer incidences and an increase in breast reconstruction surgeries. The availability of insurance coverage, such as through the Women's Health and Cancer Rights Act, enhances treatment accessibility. Technological advancements like less invasive procedures and 3D-printed implan

Description: AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.

Description: We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss. Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield. […]

Description: AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib) was significantly more effective than Humira (adalimumab) in achieving low disease activity and remission for adults with moderate to severe rheumatoid arthritis who previously did not respond to a TNF inhibitor. This outcome highlights Rinvoq’s potential to become a more central immunology offering for AbbVie as Humira encounters increased biosimilar...

Description: We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance. AbbVie is advancing its oncology […]

Description: AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

Description: Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Description: Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.

Description: Apple's Services surge, Meta's AI push, and JPMorgan's strong capital markets results headline today's top stock research picks.

Description: New data show stronger remission rates as AbbVie shifts beyond Humira.

Description: Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced this year's grant recipients of The Confidence Project: Empowering Women Entrepreneurs. After completing a 12-week "Boostcamp" and leveraging their newfound skills to pitch their business to a panel of aesthetic entrepreneurs and Allergan Aesthetics executives, 20 entrepreneurs were selected. Each entrepreneur receives a $20,000 grant funded by BOTOX® Cosmetic.

Description: As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid economic uncertainties like the prolonged government shutdown. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth, making it crucial to consider factors such as financial health and market position when evaluating investment...

Description: ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Description: AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.

Description: AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.